'Your papers, please' must never be heard in America
The men stood under bright sun in maroon blazers, an awkward collision between the NFL's freewheeling past and litigious present.
In late April, at the annual meeting for the American Academy of Neurology, the American drug developer Genzyme announced a breakthrough for one of its new multiple sclerosis drugs. The company revealed that a late-stage trial of an experimental therapy found that an astounding 65 percent of participating patients had gone without an MS relapse two years after starting treatment.
